An international phase III randomized, non-inferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: Compliance and safety of the phase III Japanese ACHIEVE trial.
2016
3550Background: Oxaliplatin/Fluoropyrimidine chemotherapy is an established adjuvant treatment for colon cancer (CC). Neurotoxicity from oxaliplatin is cumulative, dose limiting, and potentially ir...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
2
Citations
NaN
KQI